Document is current
Any future updates will be listed below
-
Authors
Fleischer, Candace C.
Gopinath, Kaundinya
Martinez Luque, Eva
Zhou, Lei
Pope, Howard L.
Peterson, Ryan B.
Alvarez, Alicarmen
McNeice, Julianna L.
Nguyen, Minh L.
Harrison, Taylor B.
Loring, David W.
Easley, Kirk A.
Gavegnano, Christina
Marconi, Vincent C.
Anderson, Albert M. L.
Tyor, William
-
Funding
Funding for this research was provided by:
National Institutes of Health (DP2NS127704)
National Institutes of Health (T32GM145445)
National Institutes of Health (P30AI050409)
National Institutes of Health (1R01MH128158)
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 29 January 2026
First Online: 6 February 2026
Declarations
:
: The study protocol was approved by the Emory University Institutional Review Board (STUDY00004498). Per the Emory University Institutional Review Board policies and procedures, Emory University agrees to uphold the ethical principles of the Belmont Report and to abide by all requirements of the applicable U.S. Department of Health and Human Services HHS, Food and Drug Administration, Department of Defense, and Department of Veterans Affairs regulations. All participants provide written informed consent prior to participation in the study. The clinical trial is overseen by an independent study monitor and DSMB. The evaluation of baricitinib to eradicate HIV-1 in the CNS has been approved by the U.S. Food and Drug Administration under Investigational New Drug number 169261.
: Written consent has been obtained from participants whose individual images and data are presented.
: The industry sponsor (Eli Lilly and Company) supplies the study drug and matching placebo but no direct monetary or funding support. Emory University holds a patent for the use of Jak inhibitors for treatment of viral infections, including HIV-1, and CG is listed as a co-inventor on this technology. VCM has received research support from Eli Lilly, Bayer, Gilead Sciences, Merck, and ViiV.
